Pfizer PFE has announced top-line data from a late-stage study which evaluated its investigational antibody-drug conjugate ...

Pfizer has reported topline data from the Phase III SigVie-002 study investigating sigvotatug vedotin in adults with ...

By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

The U.S. Food and Drug Administration on Wednesday approved a label expansion for Pfizer’s (PFE) breast cancer therapy, palbociclib, marketed as Ibrance. Accordingly, the kinase inhibitor will be ...

Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung ...

Pfizer (PFE) stock is in focus as the antibody-drug conjugate sigvotatug vedotin fails in a Phase 3 trial versus chemotherapy ...

(NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE ® (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the ...

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug ...

Pfizer Inc. PFE shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of berobenatide, an investigational GLP-1 receptor agonist for weight management.